Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Angela M. Liu"'
Autor:
Chi Tao Ng, Angela M Liu, Thomas Yau, Tan To Cheung, Paul N. M. Cheng, Gerry Gin Wai Kwok, Joanne Chiu, Roland Leung
Publikováno v:
Investigational New Drugs. 40:314-321
Introduction. We investigated the safety and efficacy of a pegylated arginase (PEG-BCT-100) in combination with chemotherapy (oxaliplatin and capecitabine) [PACOX] in advanced HCC patients. Methods. This was a single centre phase 1 trial to assess th
Publikováno v:
Investigational New Drugs. 39:1633-1640
Background The study determined the safety, pharmacokinetics/pharmacodynamics (PK/PD), and recommended Phase II dose of BCT-100 for arginine auxotrophic tumours in a non-Chinese population. Methods This is a Phase I, 3 + 3 dose-escalation, open-label
Autor:
Charing C N Chong, Anthony W.H. Chan, Leung Li, Yat M Lau, Cheuk Man Chu, Tony Mok, Paul N. M. Cheng, Simon C.H. Yu, Angela M Liu, Kelvin K. Ng, Winnie Yeo, Stephen L. Chan, Landon L. Chan
Publikováno v:
Investigational New Drugs
Background: Pegylated recombinant human arginase (PEG-BCT-100) is an arginine depleting drug. Preclinical studies showed that HCC is reliant on exogenous arginine for growth due to the under-expression of the arginine regenerating enzymes argininosuc
Autor:
Tan To Cheung, Thomas Yau, Paul N. M. Cheng, Chi Tao Ng, Gin Wai Kwok, Angela M Liu, Joanne Chiu, Roland Leung
Introduction: We investigated the safety and efficacy of PEG-BCT-100 in combination with oxaliplatin and capecitabine (PACOX) in advanced HCC patients.Methods: This was a single centre phase 1 trial to assess the safety and tolerability of PACOX. All
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::456fac107207d0fe6babe223f6fad83e
https://doi.org/10.21203/rs.3.rs-717203/v1
https://doi.org/10.21203/rs.3.rs-717203/v1
Autor:
Angela M Liu, Zhi Xu, Felix H Shek, Kwong-Fai Wong, Nikki P Lee, Ronnie T Poon, Jinfei Chen, John M Luk
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e86872 (2014)
In contrast to normal differentiated cells that depend on mitochondrial oxidative phosphorylation for energy production, cancer cells have evolved to utilize aerobic glycolysis (Warburg's effect), with benefit of providing intermediates for biomass p
Externí odkaz:
https://doaj.org/article/45321d802302417ab9575fa294725dba
Autor:
Irena Ivanovska, Chunsheng Zhang, Angela M Liu, Kwong F Wong, Nikki P Lee, Patrick Lewis, Ulrike Philippar, Dimple Bansal, Carolyn Buser, Martin Scott, Mao Mao, Ronnie T P Poon, Sheung Tat Fan, Michele A Cleary, John M Luk, Hongyue Dai
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24582 (2011)
Biomarkers derived from gene expression profiling data may have a high false-positive rate and must be rigorously validated using independent clinical data sets, which are not always available. Although animal model systems could provide alternative
Externí odkaz:
https://doaj.org/article/1a6968a013d74f12988b1620ffe531a4
Autor:
Julja Burchard, Chunsheng Zhang, Angela M Liu, Ronnie T P Poon, Nikki P Y Lee, Kwong‐Fai Wong, Pak C Sham, Brian Y Lam, Mark D Ferguson, George Tokiwa, Ryan Smith, Brendan Leeson, Rebecca Beard, John R Lamb, Lee Lim, Mao Mao, Hongyue Dai, John M Luk
Publikováno v:
Molecular Systems Biology, Vol 6, Iss 1, Pp n/a-n/a (2010)
Tumorigenesis involves multistep genetic alterations. To elucidate the microRNA (miRNA)–gene interaction network in carcinogenesis, we examined their genome‐wide expression profiles in 96 pairs of tumor/non‐tumor tissues from hepatocellular car
Externí odkaz:
https://doaj.org/article/50bc46a5e0da45ebb7e123909cce0639
Publikováno v:
Oncotarget
The Hippo pathway regulates the down-stream target Yes-associated protein (YAP) to maintain organ homeostasis, which is commonly inactivated in many types of cancers. However, how cell adhesion dysregulates the Hippo pathway activating YAP oncogene i
Publikováno v:
Hepatic Oncology. 1:323-329
SUMMARY: Hepatocellular carcinoma (HCC) remains one of the most common malignancies worldwide, ranking as the third leading cause of cancer-related death. With recent advances in understanding HCC biology, progress has been made in early detection an
Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma
Autor:
Angela M. Liu, Qi Zhang, John M. Luk, Cuiju Tang, Zhi Xu, Xinying Huo, Yongling Gong, Jianmin Bian, Jinfei Chen
Publikováno v:
Oncology Reports. 29:840-846
Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies worldwide and is highly resistant to chemotherapy. Yes-associated protein (YAP) is the downstream effector of the Hippo signaling pathway, which is frequently overexpressed in